Shares of Shield Therapeutics plc (LON:STX – Get Free Report) traded up 22.8% on Wednesday . The company traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.50 ($0.04). 5,293,617 shares were traded during trading, an increase of 126% from the average session volume of 2,340,523 shares. The stock had previously closed at GBX 2.85 ($0.04).
Shield Therapeutics Stock Performance
The stock has a market capitalization of £24.19 million, a P/E ratio of -77.33 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The company has a 50-day moving average price of GBX 2.71 and a two-hundred day moving average price of GBX 3.32.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
See Also
- Five stocks we like better than Shield Therapeutics
- What is diluted earnings per share (Diluted EPS)?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- The 3 Best Blue-Chip Stocks to Buy Now
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- What to Know About Investing in Penny Stocks
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
